A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants with Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
MD Anderson Study Status
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Myelodysplastic Syndromes, Multiple Myeloma, Anemia
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.